Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Dr Luke Jostins-Dean on being awarded a 5-year Sir Henry Dale fellowship, joint funded by the Wellcome Trust and Royal Society, entitled ‘combining genetics and high-resolution cell phenotyping to map pathways underlying inflammatory bowel disease’.

Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions; Crohn’s disease and ulcerative colitis which together affect more than 300,000 people in the UK. The ultimate aims of Luke’s project are to identify cell types and immune phenotypes that underlie IBD genetic risk and to understand how these affect disease prognosis. This research will be conducted using novel statistical methodology and experimental approaches such as single-cell RNA sequencing and mass cytometry. The project will make use of Oxford’s extensive patient cohorts, and Luke will work with clinicians and experimentalists throughout the Medical Sciences Division to link genotype to immune phenotype at scale.

Commenting on his award Luke said “I am incredibly excited to begin this project. Throughout my career I have identified over a hundred genetic risk variants for IBD, but this project will allow me to dig into what effect these variants actually have on the human immune system. Understanding the genetics of IBD will require combining statistical Big Data science with detailed molecular immunology, and this generous support from the Wellcome Trust and the Royal Society will allow us to generate the data and forge the collaborations we need to make this a reality”.

Luke will start his fellowship on 8th January 2018 and he will be based in the Kennedy, with a secondary affiliation to the Oxford Big Data Institute (BDI). Luke will collaborate with the growing number of computational researchers at the Kennedy Institute, including Dr Steve Sansom.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.